Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK presents promising phase 2a data for chronic hepatitis B treatment
Chronic hepatitis B is a major global health problem that occurs when the body’s immune system is unable to fight off the virus.
-
Low adult immunization rates decline further due to pandemic
Prior to pandemic, less than half of adults received the vaccines recommended for their age group.
-
GSK announces first participant vaccinated in phase 3 clinical trials of its 5-in-1, meningitis ABCWY vaccine candidate
The trial will evaluate safety, tolerability and immunogenicity of GSK’s MenABCWY vaccine candidate compared to Bexsero and Menveo.
-
GSK announces $10M program to advance Black people, Latinx people, women in STEM
$10 million over 10 years to help Black, Latinx and female Philadelphia students overcome obstacles to their pursuit of careers in STEM
-
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
-
GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults
GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults
-
Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine
Promising COVID-19 vaccine candidate, developed by Sanofi in partnership with GSK, selected by U.S. government’s Operation Warp Speed.
-
GSK to share evidence supporting a personalised approach to asthma treatment at ATS 2020 Virtual
GSK to share evidence supporting a personalised approach to asthma treatment at ATS 2020 Virtual
-
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
-
Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.
-
GSK begins shipping record number of its influenza vaccine doses for 2020-21 season for US market
GSK produces largest supply ever as CDC urges adults and high-risk individuals to be immunized against influenza during COVID-19 pandemic
-
GSK and CureVac announce strategic mRNA technology collaboration
GSK and CureVac announce strategic mRNA technology collaboration
-
GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma
press release
-
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir
-
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine.
-
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices
Findings presented showed healthcare providers perceived implementation of the treatment as feasible and appropriate for people with HIV.
-
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.
-
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
ViiV Healthcare will present over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020: Virtual), 6-10 July.
-
GSK Consumer Healthcare selects Publicis Production and Tag to reinvent end-to-end marketing ecosystem
GSK announced that it has formed a global partnership with Publicis Production and Tag that will reinvent its marketing ecosystem.
-
GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease
Approval marks a significant step in GSK’s global efforts to help patients with anaemia due to chronic kidney disease (CKD).
